Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsWockhardt

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Prefer Wockhardt, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that Wockhardt is the best buying opportunity within the pharma space.

    • Modi@365: Best & worst performing stocks

      CNBC-TV18‘s Varinder Bansal gives a check on the best & worst performing stocks in this last one year of Modi government.

    • Hold Wockhardt, advises Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one can hold Wockhardt.

    • Strides Arcolab may test Rs 1135-1140: Hemant Thukral

      According to Hemant Thukral of Aditya Birla Money, Strides Arcolab may touch Rs 1135-1140.

    • Exit Wockhardt, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends exiting Wockhardt.

    • Avoid Wockhardt, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may avoid Wockhardt.

    • Prefer Strides Arcolab, Sun Pharma: Deepak Shenoy

      Deepak Shenoy of Capital Mind is of the view that one may prefer Strides Arcolab and Sun Pharma.

    • Buy Wockhardt: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Wockhardt as the stock may head higher.

    • See 10-15% upside in midcap pharma space: Vineet Bhatnagar

      Vineet Bhatnagar - MD at Phillip Capital expects 10-15 percent upside in midcap pharma stocks including Glenmark Pharma, Divis Laboratories, Torrent Pharma and Cadila Healthcare.

    • Look at Wockhardt, says Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one can look at Wockhardt.

    • Sell Lupin, Wockhardt: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities recommends selling Lupin and Wockhardt.

    • Here are top 10 stocks to focus on March 24

      Here are top 10 stocks to focus on March 24 – HDFC, Wockhardt, Geometric, GMR Infra, Sun Pharma, Ranbaxy, Hero Moto, JSPL, Adani Power and Aarti Drugs.

    • Stay invested in Wockhardt, says Sharmila Joshi

      According to Sharmila Joshi of sharmilajoshi.com, one may stay invested in Wockhardt.

    • Check out: Top chart picks by market experts

      Watch the interview of Sharmila Joshi of sharmilajoshi.com who shared her readings and outlook on specific stocks and sectors & Feroze Azeez, Director-Investment Products (Private Wealth Management) at Anand Rathi Financial Services Ltd answered few personal finance queries.

    • See higher levels in Wockhardt: Ambareesh Baliga

      Ambareesh Baliga, independent market expert is of the view that one may see higher levels in Wockhardt.

    • Here are top 10 stocks to focus on March 19

      Here are top 10 stocks to focus on March 19 - ICICI Bank, TVS Motor, BPCL, Wockhardt, Raymond, Bombay Dyeing, Oberoi Realty, Mangalore Chemicals, Deepak Fertilizers and GNFC.

    • Sell Titan Company, SAIL; buy Wockhardt: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends selling Titan Company and Steel Authority of India and advises buying Wockhardt.

    • Here are top 10 stocks to keep an eye on March 11

      Here are top 10 stocks to keep an eye on March 11 - Titan, Wockhardt, JSPL, Sesa Sterlite, Bharti Airtel, Idea Cellular, CESC, Pipavav Defence, Gujarat Fluoro and CNX PSU bank index.

    • Look at Wockhardt: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher is of the view that one may look at Wockhardt.

    • Buy HUL, Dabur, Cipla, Glenmark: CK Narayan

      According to CK Narayan, MD at Growth Avenues, one can buy Hindustan Unilever, Dabur India, Cipla and Glenmark Pharma.

    • Sell Zee Entertainment: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends selling Zee Entertainment.

    • Buy Wockhardt 1650 Call, advises VK Sharma

      VK Sharma of HDFC Securities recommends buying Wockhardt 1650 Call.

    • Buy Wockhardt, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Wockhardt.

    • Buy Wockhardt, says CK Narayan

      CK Narayan, MD of Growth Avenues is of the view that one may buy Wockhardt.

    • Here are top 10 stocks to focus on February 24

      Here are top 10 stocks to focus on February 24 - Wockhardt, Federal Bank, Bharti Airtel, Idea Cellular, Reliance Communication, State Bank of India, Punjab National Bank, Bank of Baroda, Bank of India and Omaxe.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347